Can cheap medicines stay cheap? | India’s hotel growth story | The Daily Brief #486

ELI5/TLDR

The government just let two old, cheap cancer drugs get up to 50% pricier. That sounds cruel, but the alternative was no drug at all — at the capped 61-rupee price, makers were quietly walking away because platinum doubled in cost. The episode exposes the central bug in India’s drug price-control machine: it caps the finished product but has zero say over the inputs that go into it. The second story: Indian hotels just had a record quarter despite a Gulf conflict killing foreign bookings, because domestic travellers showed up in enough force to carry the whole sector.

The Full Story

One tool, two jobs that fight each other

India’s drug pricing is run by the National Pharmaceutical Pricing Authority (NPPA), set up in 1997. Everyone calls it the agency that caps prices. That’s only half its job. Its actual mandate is two things at once — keep essential medicines affordable and keep them available. Those goals pull in opposite directions, and the cisplatin/carboplatin story is what happens when they snap.

The rulebook is the Drug Price Control Order of 2013. It sorts every medicine into two buckets. “Scheduled” drugs — about 900 formulations on the national essential-medicines list (key antibiotics, insulins, cancer drugs) — get a hard ceiling price. Everything else is “non-scheduled,” left to the market but allowed to rise no more than 10% a year.

How is a scheduled drug’s ceiling set? A market-based formula. The NPPA takes every brand with at least 1% market share, averages the price to the retailer, adds a 16% margin, and that becomes the cap. Anyone priced above must come down within 45 days. Anyone already below stays below — they can’t jump up.

The case for this is real. Indians still pay a big share of health costs out of pocket — though it has fallen from over 64% in 2013–14 to roughly 43% in 2022–23. In a market where a frightened patient is choosing between dozens of brand names at wildly different prices, a cap brings genuine savings. The government claims its ceilings have saved consumers about ₹3,82 crore by late 2025, with anti-cancer drugs alone accounting for ~₹295 crore a year. The cleanest example: in 2017 the NPPA capped cardiac stents, which hospitals had been marking up by as much as 654%. Prices fell up to 85% overnight.

Where it breaks

The ceiling isn’t frozen. It’s revised every April, indexed to the Wholesale Price Index (WPI). And there’s the bug. WPI measures economy-wide inflation — steel, soap, everything. It does not track the cost of any single drug.

In 2024, overall prices increased by about 0.0055%. Which is to say, they basically remained flat.

So the ceiling barely moved — while the cost of making a specific drug climbed much faster. The NPPA caps the finished medicine but has no control over the inputs: the active ingredient, solvents, packaging, import duty, the exchange rate. When the ceiling drifts below the real cost of production, making the drug at a loss stops making sense, and companies quietly make less or stop.

That’s exactly what happened here. Cisplatin and carboplatin are platinum-based. Naprod Life Sciences told Business Standard that platinum had roughly doubled in a year — from about ₹2,000 to nearly ₹5,000 a gram — and could only be imported with a special permit that takes months. The drugs simply became unviable. The NPPA had requests to raise prices on 82 formulations; it approved only four. The backup mechanism it used is “Paragraph 19,” a clause letting the government override the formula in extraordinary circumstances.

The pattern repeats

This isn’t a one-off. In 2025, small manufacturers told NITI Aayog that unsustainable ceilings had pushed quality drugs out — they flagged cotrimoxazole, a basic antibiotic, as uneconomic. A Himachal industry body of 500+ units said raw-material, solvent and packaging costs had jumped 200–300%. With stents, foreign makers claimed the cap fell below their cost and tried pulling their newest products; hospitals then quietly recovered margin through “consumables” and room charges, and started steering patients toward stents even where a bypass would have served better.

The government keeps reaching for the emergency lever. In October 2024 it used Paragraph 19 to raise prices 50% on asthma, TB, glaucoma and thalassemia drugs; it did similar things in 2019 and 2021. As the host puts it:

If a system keeps needing emergency exceptions, what does that say about its normal rules?

And the deeper distortions are uglier than shortages. Big diversified firms cross-subsidise — they eat the loss on a capped drug and cover it from exports, patented products and uncapped chronic-disease brands. A small maker with a narrow portfolio has nothing to cross-subsidise from, so it just exits. A Center for Global Development study found caps wiped out small local generic makers who were often the only suppliers to rural pharmacies — so a saving for city buyers showed up as a stockout for the rural poor. Other research found firms gaming the formula by raising prices just before the NPPA takes its snapshot, and pulling sales reps off cheap regulated drugs to push costlier unregulated substitutes — hitting the poorest patients hardest.

The host’s closing line is the honest one: there are good reasons to protect consumers from a confusing industry, but few of them apply to a ₹61 vial whose problem isn’t greed — it’s the cost of a metal.

Indian hotels find comfort at home

The Strait of Hormuz crisis was bad for anything with international exposure — airlines rerouted, big corporate events (the “MICE” calendar — meetings, incentives, conferences, exhibitions) cancelled. IHCL, which runs the Taj, estimated ₹40–45 crore of lost revenue in the quarter. And yet it posted its 16th consecutive quarter of record performance, with revenue, profit and EBITDA all up roughly 14–15% year on year. How?

Domestic demand. It didn’t replace everything foreign guests took with them, but it was large enough to hold the sector up. The key metric hotels watch is RevPAR — revenue per available room — because it captures both occupancy and rate in one number. Premium hotels didn’t have to discount: Indian travellers filled the rooms foreign guests left. Mid-market hotels leaning on corporate bookings had a harder time. The first half of the quarter ran on business travel and weddings; by March, when international bookings dried up, leisure travellers — hill stations, beach resorts, religious destinations — kept hotels full.

This is a years-long shift, not a quarter’s fluke. MakeMyTrip reported FY26 gross bookings of $10.4 billion (~₹97,800 crore), up 10.4% in constant currency; Yatra’s room-nights booked grew over 36%. A survey found 60% of Indian travellers planned to holiday within India in summer 2026. And there’s a supply story underneath it: per Hilton, India has roughly one hotel room per 3,000 people versus one per 60 in the US. That scarcity gives operators pricing power, and everyone is building — IHCL ended the year with 630 hotels and a ~31,000-key pipeline, growing mostly by managing others’ hotels (less capital). Lemon Tree is splitting into an asset-owning company and an operating one. International brands — Marriott, Hilton, IHG — are expanding hard, notably around temple towns; Marriott says ~11% of its India hotels serve temple visitors, Hilton says ~15% of its India pipeline sits near spiritual destinations.

But the quarter wasn’t uniform. Chalet, concentrated in business hotels in Mumbai (a weak city this quarter), had the hardest time — occupancy fell nearly 8 points and rate couldn’t compensate. March hurt because Dubai/Abu Dhabi corporate-incentive trips, which cluster a few weeks after Ramadan, were wiped out by the conflict. EIH had a weak January from North India’s winter air quality and an IndiGo flight grounding in December that softened airport-hotel bookings.

When people feel less wealthy, travel is usually one of the first things they cut back on.

The open question: an RBI June survey showed household spending sentiment weakened sharply in May. The chains building aggressively are betting domestic travel is now a permanent floor under the sector. That bet only pays if domestic demand holds after foreign travel normalises and the new supply actually arrives.

Key Takeaways

The NPPA caps the price of the finished drug but has no control over inputs — active ingredient, solvents, packaging, import duty, FX. That’s the structural fault line.
Scheduled-drug ceilings are reindexed to WPI (economy-wide inflation), which has nothing to do with any specific drug’s cost. In 2024 WPI was ~0.0055% — effectively flat — while drug-making costs climbed.
Platinum roughly doubled in a year (₹2,000 → ₹5,000/gram); cisplatin and carboplatin became unviable at the ₹61 capped price and started vanishing from hospitals.
“Paragraph 19” is the government’s emergency override; it’s been used repeatedly (2019, 2021, Oct 2024 for asthma/TB/glaucoma/thalassemia drugs). Frequent use signals the normal formula is broken.
Price caps favour big diversified firms (which cross-subsidise from exports/patented/chronic-disease brands) and push out small generic makers — often the only suppliers to rural pharmacies. Caps can convert into rural stockouts.
Documented gaming: firms raise prices just before the NPPA’s snapshot to lift the average; reps get pulled off cheap regulated drugs to push costlier unregulated substitutes.
IHCL posted its 16th straight record quarter despite a ~₹40–45 crore conflict hit; revenue/profit/EBITDA up ~14–15% YoY — entirely on domestic demand.
RevPAR (occupancy × rate) is the metric; premium hotels held rate while mid-market corporate-dependent hotels softened.
India has ~1 hotel room per 3,000 people vs ~1 per 60 in the US — a supply shortage driving operator pricing power and a record construction pipeline (~96 projects, ~1.18 lakh rooms).
Chalet (Mumbai business hotels) had the worst quarter — occupancy down ~8 points; March hurt by lost Dubai/Abu Dhabi corporate-incentive trips.
Tidbits: JSW Ecomobility bid in all five cities of the 6,230 e-bus tender but won nothing; government capped retail diesel at 200 L/vehicle/day to stop bulk diversion exploiting the ₹95.2 vs ₹134.5 retail-bulk gap; SEBI proposes illiquid stocks adopt the most-active exchange’s closing price.

Claude’s Take

The first story is the better one, and the Daily Brief deserves credit for not playing the obvious “government raises cancer-drug prices, outrage” card. They actually show their working: they admit upfront that the causal chain (cap vs. platinum scarcity vs. weak rupee vs. slow permits) isn’t cleanly separable, which is more honest than most coverage. The core insight — that capping the output while leaving the inputs uncapped, then indexing to an inflation measure that has nothing to do with the product, is a design flaw that guarantees periodic emergency overrides — is genuinely well made. The distributional point lands too: caps that look like consumer wins in cities can read as stockouts in villages because they kill the small makers who serve the villages.

It isn’t perfect. The “research is mixed” hedge does a lot of work, and they cite studies (CGD, the snapshot-gaming paper) without quite letting you weigh them — the 2024 government study found supply rose after caps for stents and knee implants, which slightly undercuts the thesis and gets one sentence. The honest verdict is “caps distort, sometimes badly, but not always” — which is correct, just less tidy than the framing suggests.

The hotel story is solid, standard sector-results synthesis — RevPAR explained cleanly, the domestic-vs-foreign split is the right lens, and the supply-shortage stat (1 room per 3,000 vs 1 per 60) is the load-bearing fact. The open question they end on is the right one and they don’t pretend to answer it.

Transcription is rough throughout — “NPPA” mangled to “NPA/MPPA/NTPA,” “IHCL” to “ICL,” “EIH” to “EI,” “₹382 crore” likely meaning something larger — so treat exact figures as directional. Score: 7. Clear, intellectually honest, good structure; docked for the hedged research section and garbled numbers that you’d want to verify before quoting.

Can cheap medicines stay cheap? | India's hotel growth story | The Daily Brief #486